Barney Chantel C, Andersen Randi D, Defrin Ruth, Genik Lara M, McGuire Brian E, Symons Frank J
Gillette Children's Specialty Healthcare, 200 University Ave E., 55101, Saint Paul, MN, USA.
Department of Educational Psychology, University of Minnesota, Minneapolis, MN, USA.
Schmerz. 2022 Feb;36(1):49-58. doi: 10.1007/s00482-021-00589-8. Epub 2021 Sep 13.
Intellectual and developmental disabilities (IDD) include conditions associated with physical, learning, language, behavioural, and/or intellectual impairment. Pain is a common and debilitating secondary condition compromising functional abilities and quality of life.
This article addresses scientific and clinical challenges in pain assessment and management in individuals with severe IDD.
This Clinical Update aligns with the 2019 IASP Global Year Against Pain in the Vulnerable and selectively reviews recurring issues as well as the best available evidence and practice.
The past decade of pain research has involved the development of standardized assessment tools appropriate for individuals with severe IDD; however, there is little empirical evidence that pain is being better assessed or managed clinically. There is limited evidence available to inform effective pain management practices; therefore, treatment approaches are largely empiric and highly variable. This is problematic because individuals with IDD are at risk of developing drug-related side effects, and treatment approaches effective for other populations may exacerbate pain in IDD populations. Scientifically, we are especially challenged by biases in self-reported and proxy-reported pain scores, identifying valid outcome measures for treatment trials, being able to adequately power studies due to small sample sizes, and our inability to easily explore the underlying pain mechanisms due to compromised ability to self-report.
Despite the critical challenges, new developments in research and knowledge translation activities in pain and IDD continue to emerge, and there are ongoing international collaborations.
智力和发育障碍(IDD)包括与身体、学习、语言、行为和/或智力损伤相关的病症。疼痛是一种常见且使人衰弱的继发性病症,会损害功能能力和生活质量。
本文探讨了重度智力和发育障碍患者疼痛评估与管理中的科学和临床挑战。
本临床最新资讯与2019年国际疼痛研究协会(IASP)针对弱势群体疼痛的全球年度活动相一致,并有选择地回顾了反复出现的问题以及现有的最佳证据和实践。
过去十年的疼痛研究涉及开发适用于重度智力和发育障碍患者的标准化评估工具;然而,几乎没有实证证据表明临床上对疼痛的评估或管理有了改善。可用于指导有效疼痛管理实践的证据有限;因此,治疗方法在很大程度上是经验性的,且差异很大。这是个问题,因为智力和发育障碍患者有发生药物相关副作用的风险,而对其他人群有效的治疗方法可能会加重智力和发育障碍患者的疼痛。在科学上,我们尤其面临以下挑战:自我报告和代理报告的疼痛评分存在偏差,确定治疗试验的有效结局指标,由于样本量小而无法进行充分有力的研究,以及由于自我报告能力受损而无法轻松探究潜在的疼痛机制。
尽管面临严峻挑战,但疼痛与智力和发育障碍研究及知识转化活动仍不断有新进展,国际合作也在持续进行。